(NASDAQ: JAZZ) Jazz Pharmaceuticals's forecast annual revenue growth rate of 5.74% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Jazz Pharmaceuticals's revenue in 2025 is $4,086,695,000.On average, 9 Wall Street analysts forecast JAZZ's revenue for 2025 to be $255,376,740,148, with the lowest JAZZ revenue forecast at $252,352,170,614, and the highest JAZZ revenue forecast at $259,236,399,506. On average, 10 Wall Street analysts forecast JAZZ's revenue for 2026 to be $273,130,239,049, with the lowest JAZZ revenue forecast at $252,666,383,244, and the highest JAZZ revenue forecast at $298,227,214,684.
In 2027, JAZZ is forecast to generate $293,510,567,673 in revenue, with the lowest revenue forecast at $270,981,097,446 and the highest revenue forecast at $328,520,223,899.